Strengthening the reporting of genetic risk prediction studies: The GRIPS statement

PLoS Medicine

Volumn 8, Issue 3, 2011, Pages

  Janssens, A Cecile J W ^a   Ioannidis, John P A ^b,c,d,e,f   van Duijn, Cornelia M ^a   Little, Julian ^g   Khoury, Muin J ^h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF IOANNINA   (Greece)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF OTTAWA   (Canada)

^h NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; GENETIC RISK; GENOMICS; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; TREATMENT RESPONSE; DEVELOPING COUNTRY; FORECASTING; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; RISK ASSESSMENT; RISK FACTOR;

DEVELOPING COUNTRIES; FORECASTING; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC RESEARCH; HUMANS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS;

EID: 79953700584     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000420     Document Type: Article

References (26)

1. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, et al. (2007) The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 9: 665-674.
2. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, et al. (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119: 2408-2416.
3. Kyzas PA, Denaxa-Kyza D, Ioannidis JP, (2007) Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 99: 236-243.
4. Kyzas PA, Loizou KT, Ioannidis JP, (2005) Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 97: 1043-1055.
5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2: 416-422.
6. Kyzas PA, Denaxa-Kyza D, Ioannidis JP, (2007) Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43: 2559-2579.
7. Tzoulaki I, Liberopoulos G, Ioannidis JP, (2009) Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 302: 2345-2352.
8. von Elm E, Egger M, (2004) The scandal of poor epidemiological research. BMJ 329: 868-869.
9. Simera I, Moher D, Hoey J, Schulz KF, Altman DG, (2010) A catalogue of reporting guidelines for health research. Eur J Clin Invest 40: 35-53.
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4: e296 doi:10.1371/journal.pmed.0040296.
11. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, et al. (2009) STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 6: e22 doi:10.1371/journal.pmed.1000022.
12. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 326: 41-44.
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067-9072.
14. Janssens ACJW, Van Duijn CM, (2009) Genome-based prediction of common diseases: methodological considerations for future research. Genome Med 1: 20.
15. Khoury MJ, Gwinn M, Ioannidis JP, (2010) The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol 172: 517-524.
16. Moons KG, Altman DG, Vergouwe Y, Royston P, (2009) Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 338: b606.
17. Khoury MJ, Dorman JS, (1998) The Human Genome Epidemiology Network. Am J Epidemiol 148: 1-3.
18. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, et al. (2005) Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 97: 715-723.
19. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, et al. (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134: 663-694.
20. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. (2003) The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 138: W1-12.
21. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100 doi:10.1371/journal.pmed.1000100.
22. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, et al. (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 4: e297 doi:10.1371/journal.pmed.0040297.
23. Vandenbroucke JP, (2009) STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK.. and CONSORT: for whom does the guideline toll? J Clin Epidemiol 62: 594-596.
24. Cook NR, (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115: 928-935.
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS, (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172.
26. Janssens ACJW, Khoury MJ, (2010) Assessment of improved prediction beyond traditional risk factors: when does a difference make a difference? Circ: Cardiovasc Genet 3: 3-5.